A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)
A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia
1 other identifier
interventional
34
1 country
7
Brief Summary
Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2012
CompletedFirst Submitted
Initial submission to the registry
August 17, 2012
CompletedFirst Posted
Study publicly available on registry
August 21, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedJuly 11, 2013
July 1, 2013
10 months
August 17, 2012
July 9, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Change from baseline in hair number
24 weeks post-injection
Change from baseline in hair width
24 weeks post-injection
Time course of any treatment benefit
24 week post-injection
Study Arms (1)
Treatment
EXPERIMENTALInterventions
A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
Eligibility Criteria
You may qualify if:
- Male and female volunteers 18-50 years old, inclusive.
- Women of childbearing potential must use an adequate form of contraception during study participation.
- Hair loss consistent with Grade III-Vertex, IV, or V based on the based on the Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle, or class 1 or class 2 based on the Ludwig scale.
- Able to provide informed consent after risks and benefits of the study have been explained.
- Be willing to undergo all study procedures.
- Ability to communicate effectively with study personnel.
- Have no clinically significant disease or abnormal laboratory evaluations taken at the screening visit.
- Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study; also agrees to abstain from shaving the head during the course of the study.
You may not qualify if:
- Women who are pregnant or lactating.
- Known sensitivity to DMEM/F-12 or any component of the study material.
- Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
- Subjects who have used minoxidil or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
- A history of drug or alcohol abuse within 1 year of study enrollment.
- Participation in any other investigational study within 30 days or six half lives of its biologic activity, whichever is longer, before the scalp excision visit(s), and during the time enrolled in this study.
- Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
- Clinically significant symptoms of any acute illness within 30 days prior to excision day.
- Any condition that compromises the ability to understand or comply with study requirements.
- Clinically significant abnormal laboratory parameters.
- A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
- Clinically significant dermatologic condition in donation or study zones.
- Prior surgery in the donor or study zones.
- Insufficient hair or scarring in the donor area that might impact cell growth.
- Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Radiant Research, Inc.
Tucson, Arizona, 85710, United States
Radiant Research, Inc.
Santa Rosa, California, 95405, United States
Radiant Research, Inc.
Denver, Colorado, 80239, United States
Radiant Research, Inc.
Pinellas Park, Florida, 33781, United States
Radiant Research, Inc.
Akron, Ohio, 44311, United States
Radiant Research, Inc.
Greer, South Carolina, 29650, United States
Radiant Research, Inc.
San Antonio, Texas, 78229, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 17, 2012
First Posted
August 21, 2012
Study Start
June 1, 2012
Primary Completion
April 1, 2013
Last Updated
July 11, 2013
Record last verified: 2013-07